Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: May 9, 2024
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025
Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track
Read more at globenewswire.comNYSEARCA:MTNB (7/22/2025, 11:45:33 AM)
0.972
+0.01 (+0.88%)
Find more stocks in the Stock Screener
